IND Application Advanced With Successful Completion of Assay
Filed with ASX · · 4 pages · English
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- Clinical Advisory Committee Established to Advance Phase 2b
- Presentations at European Stroke Organisation Conference
- Argenica Receives $3.97m R&D Tax Incentive Cash Rebate
- Half Yearly Report and Accounts
- Successful Applicaton for EMA Paediatric Waiver
Later from Argenica Therapeutics
- WHO Confirms Xaranetide as INN for ARG-007
- ARG007 (Xaranetide) Completes All Three FDA Requested Assays
- ARG007 Shows Significant Neuroprotection in Concussion Study
- Appendix 4E & Annual Report to 30 June 2026
- New Mechanism Findings Offer Insights Into Phase 2 Signal
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics